Tanvex BioPharma, Inc. (TPE:6541)

Tanvex BioPharma Statistics

Total Valuation

TPE:6541 has a market cap or net worth of TWD 13.70 billion. The enterprise value is 14.66 billion.

Market Cap	13.70B
Enterprise Value	14.66B

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

TPE:6541 has 238.68 million shares outstanding. The number of shares has increased by 40.81% in one year.

Current Share Class	238.68M
Shares Outstanding	238.68M
Shares Change (YoY)	+40.81%
Shares Change (QoQ)	+6.08%
Owned by Insiders (%)	1.28%
Owned by Institutions (%)	2.03%
Float	83.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	123.43
PB Ratio	2.81
P/TBV Ratio	8.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-10.45
EV / Sales	132.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.71

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.32.

Current Ratio	2.17
Quick Ratio	1.50
Debt / Equity	0.32
Debt / EBITDA	n/a
Debt / FCF	-1.23
Interest Coverage	-26.32

Financial Efficiency

Return on equity (ROE) is -44.17% and return on invested capital (ROIC) is -16.88%.

Return on Equity (ROE)	-44.17%
Return on Assets (ROA)	-15.80%
Return on Invested Capital (ROIC)	-16.88%
Return on Capital Employed (ROCE)	-20.47%
Revenue Per Employee	554,970
Profits Per Employee	-7.01M
Employee Count	200
Asset Turnover	0.02
Inventory Turnover	0.67

Taxes

Income Tax	-3.02M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.33% in the last 52 weeks. The beta is 0.01, so TPE:6541's price volatility has been lower than the market average.

Beta (5Y)	0.01
52-Week Price Change	-14.33%
50-Day Moving Average	54.15
200-Day Moving Average	59.04
Relative Strength Index (RSI)	52.80
Average Volume (20 Days)	1,852,991

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPE:6541 had revenue of TWD 110.99 million and -1.40 billion in losses. Loss per share was -7.11.

Revenue	110.99M
Gross Profit	-26.62M
Operating Income	-1.30B
Pretax Income	-1.41B
Net Income	-1.40B
EBITDA	-1.15B
EBIT	-1.30B
Loss Per Share	-7.11

Balance Sheet

The company has 570.97 million in cash and 1.54 billion in debt, giving a net cash position of -964.41 million or -4.04 per share.

Cash & Cash Equivalents	570.97M
Total Debt	1.54B
Net Cash	-964.41M
Net Cash Per Share	-4.04
Equity (Book Value)	4.87B
Book Value Per Share	20.42
Working Capital	637.55M

Cash Flow

In the last 12 months, operating cash flow was -1.13 billion and capital expenditures -118.46 million, giving a free cash flow of -1.25 billion.

Operating Cash Flow	-1.13B
Capital Expenditures	-118.46M
Free Cash Flow	-1.25B
FCF Per Share	-5.25

Margins

Gross Margin	-23.99%
Operating Margin	-1,171.31%
Pretax Margin	-1,266.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TPE:6541 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.81%
Shareholder Yield	-40.81%
Earnings Yield	-10.24%
FCF Yield	-9.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on March 2, 2023. It was a reverse split with a ratio of 0.3335779572.

Last Split Date	Mar 2, 2023
Split Type	Reverse
Split Ratio	0.3335779572

Scores

TPE:6541 has an Altman Z-Score of 0.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.14
Piotroski F-Score	2